Busulfan Pharmacokinetic Analysis and Glutathione S-transferase (GST)Genetic Polymorphism (A1,T1,M1,P1)in Adults Undergoing Hematological Bone Marrow Transplantation (HSCT).
Phase 4
18 Years
75 Years
18 Years
75 Years
Open (Enrolling by invite only)
Both
Busulfan Pharmacokinetic Analysis, GST Genetic Polymorphism
Both
Busulfan Pharmacokinetic Analysis, GST Genetic Polymorphism
Trial Information
Busulfan Pharmacokinetic Analysis and Glutathione S-transferase (GST)Genetic Polymorphism (A1,T1,M1,P1)in Adults Undergoing Hematological Bone Marrow Transplantation (HSCT).
Inclusion Criteria:
- Malignant or Benign Diseases who need hematological stem cell transplantation as
part of their treatment
- Busulfan should be part of the preparative protocol
Exclusion Criteria:
- Known sensitivity or allergy to Busulfan
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Hepatic Veno-Occlusive Disease, Graft versus host disease
Outcome Time Frame:
every week after HSCT up to 6 month
Safety Issue:
Yes
Authority:
Israel: Ministry of Health
Study ID:
BU-AdultPK/PGx1
NCT ID:
NCT01071486
Start Date:
August 2009
Completion Date:
October 2012
Related Keywords:
- Busulfan Pharmacokinetic Analysis
- GST Genetic Polymorphism
- Busulfan
- Glutathione S-transferase
- Genetic polymorphism
- HVOD
- GVHD
Name | Location |
|---|
